TIRAP Antibody
| Code | Size | Price |
|---|
| PSI-3157-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-3157-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
TIRAP Antibody: Mal, wyatt, BACTS1, MyD88-2, MAL, Adaptor protein Wyatt, TIR domain-containing adapter protein
Application Note:
TIRAP antibody can be used for detection of TIRAP by Western blot at 1 to 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2 μg/mL. For immunofluorescence start at 10 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
TIRAP Antibody: Toll-like receptors (TLRs) are signaling molecules that recognize different microbial products during infection and serve as an important link between the innate and adaptive immune responses. These proteins act through adaptor molecules such as TIRAP and MyD88 to activate various kinases and transcription factors. In TIRAP-deficient mice, TLR signaling in response to TLR2 ligands (using either TLR1 and TLR6 as co-receptors) is totally abolished, suggesting that MyD88 and TIRAP work together and are both required for TLR2 signaling. Furthermore, these mice are also resistant to the toxic effects of LPS and show defects in NF-kappaB and MAP kinase activation, suggesting that TIRAP is also involed in TLR4 signaling.
Background References:
- Vogel SN, Fitzgerald KA, and Fenton MJ. TLRs: differential adapter utilization by toll-like receptors mediates TLR-specific patterns of gene expression. Mol. Interv. 2003; 3:466-77.
- Takeda K, Kaisho T, and Akira S. Toll-like receptors. Annu. Rev. Immunol. 2003; 21:335-76.
- Janeway CA Jr and Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002; 20:197-216.
- O'Neill LAJ, Fitzgerald FA, and Bowie AG. The Toll-IL-1 receptor adaptor family grows to five members. Trends in Imm. 2003; 24:286-9.
Buffer:
TIRAP Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
TIRAP antibody was raised against a peptide corresponding to 15 amino acids near the C-terminus of mouse TIRAP.
The immunogen is located within the last 50 amino acids of TIRAP.
The immunogen is located within the last 50 amino acids of TIRAP.
NCBI Gene ID #:
114609
NCBI Official Name:
toll-interleukin 1 receptor (TIR) domain containing adaptor protein
NCBI Official Symbol:
TIRAP
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 24, 26 kDa
Observed: 24 kDa
Observed: 24 kDa
Protein Accession #:
NP_473437
Protein GI Number:
15705407
Purification:
TIRAP Antibody is affinity chromatography purified via peptide column.
Research Area:
Innate Immunity
SPECIFICITY:
At least three isoforms of TIRAP are know to exist; this antibody detects all three isoforms.
Swissprot #:
P58753
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | TIRAP Peptide | PSI-3157P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|